Health
Prime Medicine Revives Shelved Gene Therapy After FDA Shift
Prime Medicine reverses course to seek FDA approval for a previously sidelined rare immune disease therapy, citing the agency's evolving stance on rare diseases.
Key Takeaways
- Prime Medicine revives previously shelved rare immune disease therapy
- FDA's evolving stance on rare disease approvals drove the reversal
- Prime editing offers more precise gene correction than traditional CRISPR
DE
DT Editorial AI··via endpoints.news